Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL278353 | 0.82 | CYP3A4 (0.52) | CYP3A4TSHRCA1CA2TRPA1 | |
| SCHEMBL7180551 | 0.82 | CYP3A4 (0.52) | CYP3A4TSHRCA1CA2TRPA1 | |
| SCHEMBL2891113 | 0.81 | CA1 (0.66) | CYP3A4ENPP2CA1CA2TDP1 | |
| SCHEMBL10451648 | 0.79 | CYP3A4 (0.50) | CYP3A4TSHRCA1CA2TRPA1 | |
| SCHEMBL2278953 | 0.78 | POLB (0.53) | CYP3A4TSHRCA1CA2TRPA1 | |
| SCHEMBL242025 | 0.78 | CA2 (0.68) | CYP3A4TSHRCA1CA2TDP1 | |
| SCHEMBL31148855 | 0.78 | CYP3A4 (0.48) | CYP3A4TSHRCA1CA2TRPA1 | |
| SCHEMBL165024 | 0.78 | CYP3A4 (0.48) | CYP3A4TSHRCA1CA2TRPA1 | |
| SCHEMBL10348147 | 0.78 | CYP3A4 (0.48) | CYP3A4TSHRCA1CA2TRPA1 | |
| SCHEMBL15430 | 0.78 | CYP3A4 (0.70) | CYP3A4TSHRCA1CA2TRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113214138-A | Phenylpropionic acid derivative, preparation method thereof, pharmaceutical composition and application | 中国医学科学院药物研究所 | 2021-08-06 | — | — | CN | disclosed |
| US-10723698-B2 | Inhibitors of PRMT5 and methods of their use | THE OHIO STATE UNIVERSITY (US) | 2020-07-28 | — | — | US | disclosed |
| US-20190270707-A1 | INHIBITORS OF PRMT5 AND METHODS OF THEIR USE | THE OHIO STATE UNIVERSITY | 2019-09-05 | — | — | US | disclosed |
| WO-2017024996-A1 | HYDROXY AMIDINE DERIVATIVE, PREPARATION METHOD AND USE IN MEDICINE THEREOF | 江苏恒瑞医药股份有限公司 | 2017-02-16 | — | — | WO | disclosed |
| EP-2694515-B1 | PROTEIN KINASE INHIBITORS | PHARMASCIENCE INC (CA) | 2016-08-17 | — | — | EP | disclosed |
| EP-2694515-B1 | PROTEIN KINASE INHIBITORS | PHARMASCIENCE INC (CA) | 2016-08-17 | — | — | EP | disclosed |
| US-9284318-B2 | Protein kinase inhibitors | PHARMASCIENCE, INC. (CA) | 2016-03-15 | — | — | US | disclosed |
| EP-2210880-B1 | Benzoxazinone derivatives | MSD KK (JP) | 2015-08-26 | — | — | EP | disclosed |
| US-20150210696-A1 | PROTEIN KINASE INHIBITORS | GB005, INC. | 2015-07-30 | — | — | US | disclosed |
| US-20150210696-A1 | PROTEIN KINASE INHIBITORS | GB005, INC. | 2015-07-30 | — | — | US | disclosed |
| EP-0307176-A2 | Erythromycin derivatives | BEECHAM GROUP PLC (GB) | 1989-03-15 | — | — | EP | disclosed |
| EP-0284203-A2 | Erythromycin derivatives, process for their preparation and their pharmaceutical use | BEECHAM GROUP PLC (GB) | 1988-09-28 | — | — | EP | disclosed |
| US-4663341-A | Insecticidal n-aryl-3-aryl-4,5-dihydro-1h-pyrazole-1-carboxamides | ROHM AND HAAS COMPANY (US) | 1987-05-05 | — | — | US | disclosed |
| CN-85101497-A | Process for the preparation of N-aryl-3-aryl-4, 5-dihydro-1H-pyrazole-1-carboxamides | — | 1986-07-16 | — | — | CN | disclosed |
| EP-0153127-A2 | N-aryl-3-aryl-4,5-dihydro-1H-pyrazole-1-carboxamides, processes for their production, insecticidal compositions containing them and methods for combatting insects | ROHM AND HAAS COMPANY (US) | 1985-08-28 | — | — | EP | disclosed |
| US-4140860-A | BACTERICIDES | STERLING DRUG INC. (US) | 1979-02-20 | — | — | US | disclosed |
| US-4119668-A | ANTIBACTERIAL AGENTS | STERLING DRUG INC. (US) | 1978-10-10 | — | — | US | disclosed |
| US-4085144-A | ANTIBACTERIAL | STERLING DRUG INC. (US) | 1978-04-18 | — | — | US | disclosed |
| US-4022833-A | ANTIBACTERIAL AGENTS | STERLING DRUG INC. (US) | 1977-05-10 | — | — | US | disclosed |
| US-3961061-A | INSECTICIDES, FUNGICIDES, BACTERICIDES, MITICIDES | BAYER AKTIENGESELLSCHAFT (DT) | 1976-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150210696-A1 | PROTEIN KINASE INHIBITORS | PDGFRA, PDGFRB, KDR | CYP3A4 4712/4885TSHR 3110/4885ENPP2 948/4885 |
| US-20190270707-A1 | INHIBITORS OF PRMT5 AND METHODS OF THEIR USE | PRMT5, PRMT1, PRMT3 | CYP3A4 3733/4885TSHR 2722/4885ENPP2 2250/4885 |
| US-10723698-B2 | Inhibitors of PRMT5 and methods of their use | PRMT5, PRMT1, PRMT3 | CYP3A4 3733/4885TSHR 2722/4885ENPP2 2250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.